retatrutide phase 2 diabetes weight loss 2024 study sees significant in obesity drug study Triple hormone receptor agonist retatrutide

A dose-dependent decrease in mean placebo-adjusted body weight of up to 8.96 kg was observed with LY, except in the initial cohort

During this washout period, the medication continues to exert diminishing effects

What to Expect Going Forward Interest in retatrutide continues to grow, and research around metabolic therapies is moving quickly

GLP-1 drugs have been linked to pancreatitis

If you are ready to take the next step in your journey with the support of a dedicated clinical team, we invite you to begin with our free assessment quiz to see which program is right for your unique health profile

SeekPeptides provides comprehensive peptide education resources , dosage calculators , and protocol guidance that help researchers make informed decisions regardless of their peptide source